Skip to content
Open access

Integrative Analysis of Gene and Protein Expression Data Reveals Novel Clusters for Ovarian Cancer Prognosis

Aug 2026 · International Journal of Molecular Sciences · Vol 27 · 0 citations · 68 references
Medicine

TL;DR

Integrative analysis of multi–omics data provided robust prognostic stratification in ovarian cancer while capturing the underlying molecular and biological features.

Abstract

Ovarian cancer exhibits clinical heterogeneity; reliable prognostic stratification remains challenging despite extensive biomarker research. We performed an integrative analysis of transcriptomic and proteomic data to identify prognostically distinct molecular clusters in ovarian cancer. Using The Cancer Genome Atlas dataset, RNA sequencing and reverse–phase protein array data from 146 overlapping samples were analyzed. Genes (n = 150) and proteins (n = 67) showing nominal associations with overall survival (p < 0.05) were integrated; k–means clustering identified two patient clusters with highly significant differences in survival (p = 8.59 × 10−15). The SAR2 and ACTN4 genes and their corresponding protein expression levels showed high correlations among the significant genes and proteins (correlation coefficients > 0.80). Gene set enrichment analysis revealed that genes regulated by the PAX2 and BCL6 transcription factors were significantly enriched. The identified clusters were validated across six independent public transcriptomic datasets comprising 617 patients; consistent survival separation was observed between the patient clusters (p < 0.05). Clustering based on immunohistochemistry–derived expression profiles of nine proteins in an independent patient cohort demonstrated a significant difference in survival (p = 0.04). Integrative analysis of multi–omics data provided robust prognostic stratification in ovarian cancer while capturing the underlying molecular and biological features.

Read PDF

Similar papers

Open access Aug 2026

Multi-level Transcriptomic and Machine-learning Analyses Identify MZT1 as a Proliferation-associated Prognostic Marker in Lung Adenocarcinoma

MZT1 is a proliferation-associated marker that integrates clinical risk, transcriptional programs, cellular heterogeneity, and predictive modeling in LUAD, providing a potential framework for biomarker development and risk stratification.

Dahlak Daniel Solomon, Hui-Ru Lin, Yung-Kuo Lee et al. · 0 citations
Open access Aug 2026

Integrated transcriptomic analysis and RT-qPCR validation using FFPE patient tissues reveal the role of FOXQ1 and MCM10 in ovarian cancer

This integrated transcriptomic and experimental validation study identifies FOXQ1 and MCM10 as key regulators in ovarian cancer, highlighting their potential as biomarkers for disease progression.

D. Suryandari, L. Yunaini, Khaerunissa Anbar Istiadi et al. · 0 citations
Open access Aug 2026

Integrated transcriptomic and immune-associated network analysis of breast cancer patient-derived organoids reveals candidate inflammatory biomarkers

It is suggested that IL1RAP and IRF2BP2 may be important in immune-related and candidated biomarker identification in breast cancer PDOs, and an integrated transcriptomic, enrichment and network-based analyses for a robust strategy for biomarker discovery are integrated.

S. Scippa, A. Balestrieri, M. Zanfardino et al. · 0 citations
Review Open access Aug 2026

Integrative transcriptomic analysis identifies shared coding and non-coding biomarkers in tongue squamous cell carcinoma across diverse populations

This study defines a cross-population gene signature driving TSCC through ECM remodeling and immune modulation, and validation of STC2 as a prognostic marker highlights its potential for clinical risk stratification.

Ronit Roy, Monika Rajput, Manoj Pandey · 0 citations
Open access Sep 2026

Integrated Bioinformatics Identification and Multi-Dimensional Characterization of Diagnostic Hub Genes in Colorectal Cancer

These results identify seven tissue-transcriptomic candidates with strong dataset-specific discriminative performance and provide a multidimensional biological framework warranting experimental validation and prospective clinical evaluation.

Zeynep Mutlu Coskun, Muhammet Coskun, Saime Sezer Sondaş · 0 citations
Aug 2026

Integrative analysis of TCGA data identifies hsa-miR-200a as a breast cancer-associated microRNA biomarker with exploratory serum validation.

Findings support hsa-miR-200a as a potential breast cancer-associated miRNA biomarker candidate and highlight the utility of integrative transcriptomic and exploratory clinical serum approaches for future precision diagnostics.

Kwangmin Park, Eun You Kim, Eun Ju Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.